Catalyst Pharmaceuticals: Stable Firdapse, Promising Agamree, Fycompa Challenges
Firdapse drives Catalyst Pharmaceuticals, Inc.'s revenue with a 37% CAGR since its 2019 launch, boosted by an FDA-approved 100 mg dose expansion. Agamree targets DMD and has so far generated $46 million in its first 10 months, which does attest to its strong growth potential. However, Fycompa still faces generic competition starting May 2025. So it remains to be seen if they'll achieve a “managed and gradual” revenue decline.
Here's What's Driving Catalyst Pharmaceuticals Stock 8% Higher Today
Shares of drugmaker Catalyst Pharmaceuticals (CPRX 5.54%) are up a little more than 8% as of midday on Thursday, down slightly from an intraday peak gain of nearly 13%. The company's fourth-quarter results posted after Wednesday's close were markedly better than expected.
Catalyst Pharmaceuticals, Inc. (CPRX) Q4 2024 Earnings Call Transcript
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Michael Kalb - Executive Vice President & Chief Financial Officer Richard Daly - President and Chief Executive Officer Jeff Del Carmen - Executive Vice President, Chief Commercial Officer Steven Miller - Executive Vice President, Chief Operating Officer and Chief Scientific Officer Gary Ingenito - Chief Medical and Regulatory Officer Conference Call Participants Charles Duncan - Cantor Fitzgerald Asim Rana - Truist Securities Benjamin Paluch - Citi Investment Research Joseph Catanzaro - Piper Sandler Joel Beatty - Baird Felix Ampomah - Stephens Operator Greetings, and welcome to the Catalyst Pharmaceuticals Fourth Quarter and Full-Year 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
CPRX Q4 Earnings Beat, Firdapse Sales Boost Revenues, Stock Up
Catalyst stock gains on strong fourth-quarter results, beating earnings and revenue estimates, primarily driven by Firdapse sales.
Catalyst (CPRX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for Catalyst (CPRX) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Catalyst Pharmaceutical (CPRX) Tops Q4 Earnings and Revenue Estimates
Catalyst Pharmaceutical (CPRX) came out with quarterly earnings of $0.70 per share, beating the Zacks Consensus Estimate of $0.52 per share. This compares to earnings of $0.53 per share a year ago.
Catalyst Remains a Big Money Favorite
Catalyst Pharmaceuticals, Inc. (CPRX) shares keep gaining on Big Money buys.
This Drug Stock Sits On A Strong Earnings Foundation As It Tests New Entry
This pharma stock has made strong gains over the past 12 months thanks to its strong earnings. Now it is testing a fresh buy point.
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Catalyst Pharmaceuticals: The Stars Align For Flagship FIRDAPSE
Catalyst Pharmaceuticals' investment merits are bolstered by a favorable settlement announced on 01/08/2025. CPRX generates income from three products, primarily FIRDAPSE for LEMS and FYCOMPA for epilepsy. Detailed revenue breakdown from Q3 2024 10-Q highlights FIRDAPSE as the main revenue driver.
CPRX Stock Rises 17% on Settling Firdapse Patent Litigation With Teva
Catalyst stock gains 17% as it settles Firdapse patent litigation with Teva protecting the drug's exclusivity in the United States till Feb. 25, 2035.
